INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Press Releases

INO-3107 Awarded the Innovation Passport Designation Under U.K. Government’s Innovative Licensing and Access Pathway

Posted on July 11, 2024

INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

Posted on July 2, 2024

INOVIO Added to Russell 2000® Index Effective July 1, 2024

Posted on July 1, 2024

INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.

Posted on June 4, 2024

INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights

Posted on May 13, 2024

INOVIO to Participate in Upcoming Investor Conferences in May

Posted on April 29, 2024

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

Posted on April 29, 2024

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Posted on April 15, 2024

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

Posted on March 26, 2024

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Posted on March 6, 2024

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.